Related Experiment Video
Updated: Feb 1, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants
Bo-Hao Tang1, Yue-E Wu1, Chen Kou2
1Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Insights
This study established evidence-based amoxicillin dosage regimens for neonates and young infants. New dosing recommendations ensure optimal treatment of bacterial infections by considering developmental pharmacokinetics and pharmacodynamics.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Amoxicillin is a key antibiotic for neonatal bacterial infections.
- Significant variability exists in current amoxicillin dosing regimens for neonates.
- Limited pharmacokinetic data is available for preterm neonates.
Purpose of the Study:
- To evaluate population pharmacokinetics of amoxicillin in a large cohort of neonates and young infants.
- To develop evidence-based amoxicillin dosage regimens using developmental pharmacokinetics-pharmacodynamics.
- To optimize antibiotic therapy for neonatal bacterial infections.
Main Methods:
- Prospective, multicenter pharmacokinetic study with opportunistic sampling.
- Amoxicillin plasma concentrations measured by high-performance liquid chromatography.
- Population pharmacokinetic analysis using NONMEM, with covariate analysis and model validation.
Main Results:
- A two-compartment model identified current weight, postnatal age, and gestational age as significant covariates.
- Simulations showed current regimens achieve pharmacodynamic targets in 79.0%-99.0% of neonates, depending on sepsis type and prematurity.
- Established new dosage regimens based on developmental pharmacokinetics-pharmacodynamics.
Conclusions:
- Population pharmacokinetics of amoxicillin in neonates and young infants were characterized.
- Evidence-based amoxicillin dosage regimens were established for improved neonatal infection treatment.
- Optimized dosing can enhance therapeutic outcomes and minimize resistance.
Abstract:
Amoxicillin is widely used to treat bacterial infections in neonates. However, considerable intercenter variability in dosage regimens of antibiotics exists in clinical practice. The pharmacokinetics of amoxicillin has been described in only a few preterm neonates. Thus, we aimed to evaluate the population pharmacokinetics of amoxicillin through a large sample size covering the entire age range of neonates and young infants and to establish evidence-based dosage regimens based on developmental pharmacokinetics-pharmacodynamics. This is a prospective, multicenter, pharmacokinetic study using an opportunistic sampling design. Amoxicillin plasma concentrations were determined using high-performance liquid chromatography. Population pharmacokinetic analysis was performed using NONMEM. A total of 224 pharmacokinetic samples from 187 newborns (postmenstrual age range, 28.4 to 46.3 weeks) were available for analysis. A two-compartment model with first-order elimination was used to describe population pharmacokinetics. Covariate analysis showed that current weight, postnatal age, and gestational age were significant covariates. The final model was further validated for predictive performance in an independent cohort of patients. Monte Carlo simulation demonstrated that for early-onset sepsis, the currently used dosage regimen (25 mg/kg twice daily [BID]) resulted in 99.0% of premature neonates and 87.3% of term neonates achieving the pharmacodynamic target (percent time above MIC), using a MIC breakpoint of 1 mg/liter. For late-onset sepsis, 86.1% of premature neonates treated with 25 mg/kg three times a day (TID) and 79.0% of term neonates receiving 25 mg/kg four times a day (QID) reached the pharmacodynamic target, using a MIC breakpoint of 2 mg/liter. The population pharmacokinetics of amoxicillin was assessed in neonates and young infants. A dosage regimen was established based on developmental pharmacokinetics-pharmacodynamics.
More Related Videos
Related Concept Videos
Drug Dosing: Infants and Children
Analysis of Population Pharmacokinetic Data
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Conservation of Small Populations

